Johnson & Johnson splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 28, 2025 was Innovative Medicine at $60.4 billion, 64% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 28, 2025 was Innovative Medicine at $60.4 billion, 64% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 27, 2026
|
FY 2025
Dec 28, 2025
|
FY 2024
Dec 29, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Jan 1, 2023
|
FY 2021
Jan 2, 2022
|
FY 2020
Jan 3, 2021
|
FY 2019
Dec 29, 2019
|
FY 2018
Dec 30, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Jan 1, 2017
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
99,335
|
94,193
|
88,821
|
85,159
|
79,990
|
78,740
|
82,584
|
82,059
|
81,581
|
—
|
—
|
| Operating segments | |||||||||||
| Innovative Medicine |
64,330
+9.1%
share 64.8%
|
60,401
+6.0%
share 64.1%
|
56,964
+4.0%
share 64.1%
|
54,759
+4.2%
share 64.3%
|
52,563
+1.7%
share 65.7%
|
51,680
share 65.6%
|
—
|
—
|
—
|
—
|
—
|
| Med Tech |
35,005
+5.5%
share 35.2%
|
33,792
+6.1%
share 35.9%
|
31,857
+4.8%
share 35.9%
|
30,400
+10.8%
share 35.7%
|
27,427
+1.4%
share 34.3%
|
27,060
share 34.4%
|
—
|
—
|
—
|
—
|
—
|
| Sales mix | |||||||||||
| Innovative Medicine |
64,330
+9.1%
share 64.8%
|
60,401
+6.0%
share 64.1%
|
56,964
+4.0%
share 64.1%
|
54,759
+4.2%
share 64.3%
|
52,563
+1.7%
share 65.7%
|
51,680
share 65.6%
|
—
|
—
|
—
|
—
|
—
|
| Med Tech |
35,005
+5.5%
share 35.2%
|
33,792
+6.1%
share 35.9%
|
31,857
+4.8%
share 35.9%
|
30,400
+10.8%
share 35.7%
|
27,427
+1.4%
share 34.3%
|
27,060
share 34.4%
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JNJ (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- NJ
- Headquarters
- New Brunswick, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 200406
- Former names
- JOHNSON & JOHNSON ET AL (until Jan 23, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.